Early Relapse in Follicular Lymphoma: High Risks and High Stakes

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

and Seattle Cancer Care Alliance, Seattle, WA; Oncology Division, Department of Medicine, University of Wisconsin–Madison, Madison, WI; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY; Division of Hematology, Mayo Clinic, Rochester, MN; Gile...

High-Dose Therapy for Follicular Lymphoma

Randomized trials are defining the role of autologous stem-cell transplantation in aggressive non-Hodgkin’s lymphoma (NHL), but there is less experience with this treatment in follicular lymphomas. Approximately 40% to 50% of patients with follicular NHL are in remission 4 to 5 years following autologous stem-cell transplantation. Results from phase II studies and retrospective analyses are rem...

High-dose therapy for follicular lymphoma.

Most patients with advanced-stage follicular non-Hodgkin's lymphoma (NHL) are not cured with conventional therapy. The use of high-dose therapy and autologous stem-cell transplantation in patients with relapsed follicular NHL has received increasing attention. Several large studies suggest a disease-free survival rate of approximately 40% among patients transplanted during sensitive relapse, al...

High-Stakes Interpretation

High-Stakes Testing

I review the literature on the impact on student achievement of high-stakes testing. Its popularity as a mechanism for holding educators accountable has triggered studies to examine whether its promise to increase student learning has been fulfilled. The review concludes there is no consistent evidence to suggest high-stakes testing leads to increases in student learning. Some evidence suggests...